The invention discloses an
alkannin acting target spot screened based on an LIP-MS technology and application, and relates to the technical field of medicines.The
alkannin acting target spot is technically characterized in that a
protein sample is subjected to restrictive enzymolysis through wide specific
protease, and the characteristic that the conformation stability of a binding region
peptide fragment can be improved through binding of a
medicine and
target protein is utilized; further,
trypsin is used for carrying out secondary enzymolysis, a
quantitative proteomics technology is used for collecting
peptide fingerprint spectrums, specific conformation maintaining
peptide fragments obtained after
drug treatment are screened out by analyzing and comparing changes of the peptide
fingerprint spectrums of a control group and a
drug treatment group,
target protein information corresponding to the peptide fragments is identified through
database matching, and compared with a traditional DARTS method, the method has the advantages that the method is simple and convenient, and the efficiency is high. According to non-labeled
drug target analysis based on peptide
fingerprint spectrum, a detected object is converted into
a peptide fragment from a
protein, and the interaction between a low-affinity multi-
target drug and the
protein, low-abundance protein and local conformation change information of high-molecular-weight protein are expected to be represented, so that the accuracy and sensitivity of
target analysis are improved.